Skip to content
Screener

Roivant Sciences ROIV Total Revenue

Discontinued — last reported Q1 '26

Total Revenue at other companies

Amgen logo
AmgenAMGN
$10.05B+9.5%
Moderna logo
ModernaMRNA
$145M+2.1%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Regenxbio logo
RegenxbioRGNX
$108.02M+406%
Revvity logo
RevvityRVTY
$729.69M+1.3%

Segments

By segment

See full
Reportable Segment$1.44M-33.5%

Other financials

Income statement

See full
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$26.55B+224%
Enterprise value$26.58B+224%
P/S3,524.4×+3,172×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Roivant Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q2 2026
Accession
0001635088-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025
Revenue$1,442$2,170
Operating expenses:
Cost of revenues284154
Research and development (includes $8,721 and $11,099 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)202,016152,919
General and administrative (includes $74,621 and $71,079 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively)165,527134,019
Total operating expenses367,827287,092
Gain on litigation settlement392
Loss from operations(365,993)(284,922)

Item 1. Financial Statements (Unaudited).

FAQ

What is Roivant Sciences's total revenue?
Roivant Sciences (ROIV) reported total revenue of $1.44M in Q2 2026.
How has Roivant Sciences's total revenue changed year-over-year?
Roivant Sciences's total revenue decreased by 33.5% year-over-year, from $2.17M to $1.44M.
What is the long-term trend for Roivant Sciences's total revenue?
Over 4 years (2021 to 2025), Roivant Sciences's total revenue has grown at a -37.8% compound annual growth rate (CAGR), from $55.29M to $8.26M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Roivant Sciences's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude